Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Depression 4Polycystic Ovary Syndrome 2Depressive Disorder, Major 2Neoplasms 1Lymphoma, Follicular 1Hot Flashes 1Head and Neck Neoplasms 1ENT Cancer 1Breast Neoplasms 1Asthma 1

Interventions

Gemcitabine 109Paclitaxel 92Carboplatin 79pembrolizumab 75Bevacizumab 75Surveys and Questionnaires 70Docetaxel 69Cisplatin 67Nivolumab 48Exercise 48Capecitabine 48Cyclophosphamide 47Sorafenib 43Fluorouracil 43Irinotecan 42Pemetrexed 37Albumin-Bound Paclitaxel 35Radiotherapy 34Dexamethasone 34Blood Specimen Collection 34Oxaliplatin 31Leucovorin 31Erlotinib Hydrochloride 31trametinib 30130-nm albumin-bound paclitaxel 29Cetuximab 28Therapeutics 26Ipilimumab 26Standard of Care 25Methods 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neoplasms × Escitalopram × Clear all
NCT00352885 2018-09-14

Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment

Emory University

Phase 4 Completed
20 enrolled 11 charts

Depression, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡